Lupin Ltd has recently launched injectable osteoarthritis drug Hyalgan in India. In fact, Hyalgan was the first FDA approved hyaluronan therapy.The drug, which is a natural liquid injected into the knees to relieve pain caused due to osteoarthritis, has been test-marketed by Lupin over the last six months across the country.
The options for treating OA include:
- COX-2 inhibitors
- Mild Narcotics
- Local pain-relieving creams
- Viscosupplementation– These procedures involve the injection of gel-like substances (hyaluronates) into a joint to supplement the viscous properties of synovial fluid. Currently, these injections are approved for osteoarthritis of the knee joint, when more conservative treatments have failed.
Hyalgan is recommended for patients of stage 1 to 3 of OA to relieve the acute pain associated with it. Hyalgan can also delay the progression of OA when taken regularly as per the schedule.
The procedure for Hyalgan injections is explained here. Though many doctors know about this medication, not many are skilled enough to use this intra-articular injection. it would need a massive medical communication process to train most doctors in using this treatment option in the OPD. This communication would ideally be in the form an animated 2D or 3D video, with interactivity and notes.Such videos can then be distributed to relevant doctors, offline on a compact disc or online via medical forums and websites.
The Hyalgan molecule is originally developed by Italian drug maker FIDIA SpA.
According to a recently concluded survey, the market for osteoarthritis is currently pegged at Rs 150 crore. In India OA is the 2nd most prevalent disease in the age group of 25-30 years and affects more than 12 per cent of the population. Hyalgan injections are given as a series of 5 injections. Each injection is given once a week.